Details of the Drug

General Information of Drug (ID: DM1PRT6)

Drug Name

M710

Synonyms

637-01-4; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride; N1,N1,N4,N4-tetramethylbenzene-1,4-diamine dihydrochloride; N,N,N',N'-Tetramethyl-1,4-phenylenediamine Dihydrochloride; UNII-66W8HKA51X; MFCD00012482; 66W8HKA51X; tetramethyl-p-phenylenediamine dihydrochloride; 1,4-Benzenediamine, N,N,N',N'-tetramethyl-, dihydrochloride; NSC36730; 1,4-Benzenediamine, N1,N1,N4,N4-tetramethyl-, hydrochloride (1:2); 1-N,1-N,4-N,4-N-tetramethylbenzene-1,4-diamine;dihydrochloride; Wursters Reagent; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, 99%; EINECS 211-274-8; NSC 36730; TMPPD; ACMC-1B8O0; SCHEMBL379125; DTXSID2060915; N,N,N',N'-Tetramethyl-para-phenylenediamine dihydrochloride; ANW-34710; AKOS005254702; MCULE-3840175847; VZ32824; AS-14819; SY061584; 3-(4-Bromo-1H-pyrazol-1-yl)propanoicacid; DB-054526; FT-0629355; ST50308398; Tetramethyl-p-phenylene diamine hydrochloride; 1,4-Bis(dimethylamino)benzene dihydrochloride; X-4255; N,N,N',N'-Tetramethyl-p-phenylenediamine 2HCl; N,N,N',N'-Tetramethyl-p-phenylenediamine DiHCl; W-104885; Q27264036; [4-(dimethylamino)phenyl]dimethylamine, chloride, chloride; N,N,N\\',N\\'-Tetramethyl-p-phenylenediamine dihydrochloride; N1,N1,N4,N4-Tetramethyl-1,4-benzenediamine Dihydrochloride; p-Phenylenediamine, N,N,N',N'-tetramethyl-, dihydrochloride (8CI); N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, >=95%, powder; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, >=97.0% (AT)

Indication

Disease Entry	ICD 11	Status	REF
Diabetic macular edema	9B71.02	Phase 3	[1]

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

237.17

Logarithm of the Partition Coefficient

Not Available

Rotatable Bond Count

Hydrogen Bond Donor Count

Hydrogen Bond Acceptor Count

Chemical Identifiers

Formula: C10H18Cl2N2
IUPAC Name: 1-N,1-N,4-N,4-N-tetramethylbenzene-1,4-diamine;dihydrochloride
Canonical SMILES: CN(C)C1=CC=C(C=C1)N(C)C.Cl.Cl
InChI: InChI=1S/C10H16N2.2ClH/c1-11(2)9-5-7-10(8-6-9)12(3)4;;/h5-8H,1-4H3;2*1H
InChIKey: FBHKTSXMTASXFJ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 71561
CAS Number: 637-01-4
TTD ID: D4Z5CU

Drug ADMET Endpoint Profile (DAE)^NEW

Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial growth factor (VEGF)	TT9HKJA	VEGFA_HUMAN ; VEGFB_HUMAN ; VEGFC_HUMAN ; VEGFD_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Ly6/PLAUR domain-containing protein 6 (LYPD6)	OTT45DF7	LYPD6_HUMAN	Drug Response	[2]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health.
2	Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. Environ Health Perspect. 2015 May;123(5):458-66. doi: 10.1289/ehp.1408775. Epub 2015 Jan 13.